Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Search content at Experts@Minnesota
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Datasets
Press/Media
Activities
Fellowships, Honors, and Prizes
Impacts
PARP inhibitors for homologous recombination-deficient prostate cancer
Eric S. Christenson
,
Emmanuel S. Antonarakis
Research output
:
Contribution to journal
›
Review article
›
peer-review
25
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'PARP inhibitors for homologous recombination-deficient prostate cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Prostate Cancer
100%
PARP Inhibitors (PARPi)
100%
Homologous Recombination Deficiency
100%
Homologous Recombination
75%
Castration-resistant Prostate Cancer
50%
Poly (ADP-ribose) Polymerase Inhibition
50%
Novel Therapeutics
25%
Mechanism of Action
25%
Therapeutic Potential
25%
Molecular Techniques
25%
Drug Class
25%
Next-generation Sequencing Technology
25%
Castration-resistant
25%
Cancer Mortality
25%
Non-canonical
25%
Patient numbers
25%
Clinical Significance
25%
Cancer Causes
25%
Appropriate Treatment
25%
Prostate Carcinoma
25%
Expert Opinion
25%
Biallelic
25%
Monoallelic
25%
Resistant Disease
25%
Treatment Sequence
25%
Pathway mutation
25%
Cancer Population
25%
Homologous Recombination Pathway
25%
Area Cover
25%
Homologous Recombination Proficient
25%
Cancer Subgroups
25%
Substantial Burden
25%
Germline
25%
Patient Will
25%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
100%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase
33%
Malignant Neoplasm
16%
Prostate Adenocarcinoma
16%
Diseases
16%